Moreover, a large number of evidence indicates that ACL is up-regulated or activated in lung, prostate, bladder, breast, liver, stomach, and colon cancers [7,8], and its inhibition by chemical inhibitors or RNAi dramatically suppresses proliferation of certain types of tumor cells in vitro and in vivo, making ACL a promising therapeutic target to counteract cancer growth and progression [9,10,11]. This evidence concerns the gene ACLY and malignant colon neoplasm.